Polyphor’s balixafortide activity in advanced Her2-negative HR+ metastatic breast cancer fortifies Phase III chances

Breast Cancer-1
Since Her2-negative HR+ patients on hormonal therapies and CDK4/6 inhibitors are living longer, there is a need for therapies such as balixafortide once patients relapse on prior therapies. Credit: Angiola Harry on Unsplash